Maina Bhaman is Director of Healthcare Investments at Touchstone Innovations. Maina has led a number of investments in Touchstone Innovations’ healthcare portfolio including recent investments into PsiOxus Therapeutics and Cellmedica . Maina currently serves on the board of PsiOxus Therapeutics, Pulmocide, Autifony Therapeutics, Cell Medica and Topivert Pharma. Maina joined Touchstones Innovations in 2006 and prior to that worked in the research and development team at Celltech (previously Oxford Glyco Sciences). Maina’s experience includes Chimeric Therapies, a cell therapy start-up based in Philadelphia and GeneMedicine, a gene therapy company based in Houston, Tx. Maina has a BSc from the University of Texas at Austin and an MBA from the Imperial Business School.